<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01950884</url>
  </required_header>
  <id_info>
    <org_study_id>LISTEN</org_study_id>
    <secondary_id>2013-003465-33</secondary_id>
    <nct_id>NCT01950884</nct_id>
  </id_info>
  <brief_title>Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis</brief_title>
  <official_title>A Randomised Controlled Trial of Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Palermo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Palermo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  NAFLD (Non-alcoholic fatty liver disease) has become the most common cause of liver
           disease in Western countries (hepatic manifestation of insulin resistance);

        -  NAFLD represents a cardiovascular risk factor;

        -  Lifestyle modification(weight loss)is the effective medical treatment recommended for
           NASH (Non-alcoholic Steatohepatitis);

        -  Ezetimibe could represent a novel safe treatment for NAFLD (Patel 2006. Here the
           investigators propose a Randomized Controlled Pilot Trial to evaluate the addictive
           effect of ezetimibe on liver histology, biochemical and sonographic parameters in a
           small (n.40) number of NASH patients randomized for 12 months in two arms: lifestyle vs
           lifestyle+ezetimibe.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      to evaluate the addictive effect of ezetimibe on liver histology, biochemical and sonographic
      parameters in a small (n.40) number of NASH patients randomized for 12 months in two arms:
      lifestyle vs lifestyle+ezetimibe.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HISTOLOGICAL IMPROVEMENT IN THE SEVERITY OF NASH</measure>
    <time_frame>52 WEEKS</time_frame>
    <description>either improvement in NAS by at least 2 points spread across at least 2 of the NAS components or post-treatment NAS of 3 points or less;
at least 1 point improvement in the score for ballooning degeneration;
no worsening of the fibrosis score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in individual components of NAS score</measure>
    <time_frame>6 weeks, 24 weeks, 52 weeks</time_frame>
    <description>Changes in:
steatosis, lobular inflammation and hepatocellular balloonin;
fibrosis;
serum aminotransferase levels
anthropometric measures, visceral adiposity index (VAI), insulin resistence, lipid profile and liver elastometry.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in the prevalence and severity of metabolic syndrome and the cardiovascular risk profile (Framingham calculator)</measure>
    <time_frame>52 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>•Non-alcoholic Steatohepatitis (NASH)</condition>
  <arm_group>
    <arm_group_label>Ezetimibe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ezetimibe tablets plus lifestyle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lifestyle</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>lifestyle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe</intervention_name>
    <description>Ezetimibe tablets</description>
    <arm_group_label>Ezetimibe</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Lifestyle</intervention_name>
    <description>lifestyle</description>
    <arm_group_label>Ezetimibe</arm_group_label>
    <arm_group_label>lifestyle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1.Patients older 18 years

          -  2.Histological diagnosis of possible or definite NASH, according to Kleiner scorw,
             within 6 months before randomization -

        Exclusion Criteria:

          -  1)Average alcohol consumption &gt; 20 g per day in women and &gt; 30 g per day in men

          -  2)other causes of chronic liver disease 3) History of or planned gastrointestinal
             bypass or any additional bariatric surgery/intervention 4)Hepatic cirrhosis with
             Child-Pugh score of B or C, and/or concomitant HCC 5)Recent(within 6 months) or
             concomitant use of agents known to cause hepatic steatosis 7)Recent(within 6
             months)change in dose/regimen or first treatment with vitamin E, C, betaine,
             s-adenosylmethionine, ursodeoxycholate, sylimarin, fibrate, statin, pentoxyfilline,
             angiotensin II inhibitors, orlistat, sibutramine 8)Ongoing or recent therapy (within 6
             months) with vitamin D or with medications known to affect vitamin D3 metabolism 9)Any
             additional condition that might interfere with optimal partecipation in the study,
             according to Investigators opinion; 10)Be pregnant or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maurizio Averna, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Università degli studi di Palermo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dipartimento Biomedico di Medicina Interna e Specialistica Di.Bi.M.I.S.</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Hughes EA, Tracey I, Singhal S, Patel J. Unexpected beneficial effect in the use of ezetimibe in non-alcoholic fatty liver disease. Med Hypotheses. 2006;67(6):1463-4. Epub 2006 Jul 10.</citation>
    <PMID>16831521</PMID>
  </reference>
  <reference>
    <citation>Petta S, Muratore C, Craxì A. Non-alcoholic fatty liver disease pathogenesis: the present and the future. Dig Liver Dis. 2009 Sep;41(9):615-25. doi: 10.1016/j.dld.2009.01.004. Epub 2009 Feb 14. Review.</citation>
    <PMID>19223251</PMID>
  </reference>
  <reference>
    <citation>Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003 Apr;37(4):917-23. Erratum in: Hepatology. 2003 Aug;38(2):536.</citation>
    <PMID>12668987</PMID>
  </reference>
  <reference>
    <citation>Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology. 2005 Jul;42(1):44-52.</citation>
    <PMID>15895401</PMID>
  </reference>
  <reference>
    <citation>Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006 Oct;44(4):865-73.</citation>
    <PMID>17006923</PMID>
  </reference>
  <reference>
    <citation>Fassio E, Alvarez E, Domínguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology. 2004 Oct;40(4):820-6.</citation>
    <PMID>15382171</PMID>
  </reference>
  <reference>
    <citation>Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005 Jul;129(1):113-21.</citation>
    <PMID>16012941</PMID>
  </reference>
  <reference>
    <citation>Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia. 2008 Nov;51(11):1947-53. doi: 10.1007/s00125-008-1135-4. Epub 2008 Sep 2. Review.</citation>
    <PMID>18762907</PMID>
  </reference>
  <reference>
    <citation>Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, Fava JL, Wing RR. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010 Jan;51(1):121-9. doi: 10.1002/hep.23276.</citation>
    <PMID>19827166</PMID>
  </reference>
  <reference>
    <citation>Hickman IJ, Jonsson JR, Prins JB, Ash S, Purdie DM, Clouston AD, Powell EE. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut. 2004 Mar;53(3):413-9.</citation>
    <PMID>14960526</PMID>
  </reference>
  <reference>
    <citation>Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010 May 6;362(18):1675-85. doi: 10.1056/NEJMoa0907929. Epub 2010 Apr 28.</citation>
    <PMID>20427778</PMID>
  </reference>
  <reference>
    <citation>Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006 Nov 30;355(22):2297-307.</citation>
    <PMID>17135584</PMID>
  </reference>
  <reference>
    <citation>Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology. 2010 Jul;52(1):79-104. doi: 10.1002/hep.23623.</citation>
    <PMID>20578268</PMID>
  </reference>
  <reference>
    <citation>Subramanian S, Goodspeed L, Wang S, Kim J, Zeng L, Ioannou GN, Haigh WG, Yeh MM, Kowdley KV, O'Brien KD, Pennathur S, Chait A. Dietary cholesterol exacerbates hepatic steatosis and inflammation in obese LDL receptor-deficient mice. J Lipid Res. 2011 Sep;52(9):1626-35. doi: 10.1194/jlr.M016246. Epub 2011 Jun 20.</citation>
    <PMID>21690266</PMID>
  </reference>
  <reference>
    <citation>Davies JP, Scott C, Oishi K, Liapis A, Ioannou YA. Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia. J Biol Chem. 2005 Apr 1;280(13):12710-20. Epub 2005 Jan 25.</citation>
    <PMID>15671032</PMID>
  </reference>
  <reference>
    <citation>Chan DC, Watts GF, Gan SK, Ooi EM, Barrett PH. Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet. Diabetes Care. 2010 May;33(5):1134-9. doi: 10.2337/dc09-1765. Epub 2010 Feb 25.</citation>
    <PMID>20185740</PMID>
  </reference>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2013</study_first_submitted>
  <study_first_submitted_qc>September 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2013</study_first_posted>
  <last_update_submitted>September 23, 2013</last_update_submitted>
  <last_update_submitted_qc>September 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Palermo</investigator_affiliation>
    <investigator_full_name>Maurizio R. Averna</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>•Non-alcoholic Steatohepatitis (NASH)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

